Doxepin

Source product is Doxepin 10 mg Capsules (UK SPC, antidepressant indication). The optimum oral dose depends on the severity of the condition and individual response. Many patients respond satisfactorily to 75 mg daily; for those who do not, adjust according to response. Where insomnia is a troublesome symptom, divide the total daily dose so that a higher proportion is given in the evening; if drowsiness is a side effect, use the same regimen or reduce the dose. Once a satisfactory response is obtained it is often possible to reduce the dose for maintenance. The optimal antidepressant effect may not be evident for two to three weeks. Elderly: dose selection should be cautious, starting at the low end of the dosing range; half the normal maintenance dose may be sufficient, and once-a-day dosing in geriatric patients must be adjusted carefully. Hepatic impairment: dosage reduction may be required. Paediatric: safety and efficacy in children under 18 years have not been established. Note that the US label fetched in the same bundle is a different product and indication - low-dose doxepin tablets 3-6 mg once daily within 30 minutes of bedtime for insomnia, total daily dose not to exceed 6 mg - and that 6 mg/day ceiling does not apply to the UK antidepressant SPC dosing above. eMC section 4.5 was not captured in this bundle (section 4.4 truncated at the source-fetch limit), so the interactions listed are mostly from the US label.